JP2022530773A5 - - Google Patents

Info

Publication number
JP2022530773A5
JP2022530773A5 JP2021563640A JP2021563640A JP2022530773A5 JP 2022530773 A5 JP2022530773 A5 JP 2022530773A5 JP 2021563640 A JP2021563640 A JP 2021563640A JP 2021563640 A JP2021563640 A JP 2021563640A JP 2022530773 A5 JP2022530773 A5 JP 2022530773A5
Authority
JP
Japan
Prior art keywords
item
car
cells
car polypeptide
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021563640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530773A (ja
JP7595583B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/030435 external-priority patent/WO2020223327A1/en
Publication of JP2022530773A publication Critical patent/JP2022530773A/ja
Publication of JP2022530773A5 publication Critical patent/JP2022530773A5/ja
Priority to JP2024205060A priority Critical patent/JP2025028959A/ja
Application granted granted Critical
Publication of JP7595583B2 publication Critical patent/JP7595583B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021563640A 2019-04-30 2020-04-29 抗原特異的ｃｄ１９標的化ｃａｒ－ｔ細胞 Active JP7595583B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024205060A JP2025028959A (ja) 2019-04-30 2024-11-26 抗原特異的ｃｄ１９標的化ｃａｒ－ｔ細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962840774P 2019-04-30 2019-04-30
US62/840,774 2019-04-30
PCT/US2020/030435 WO2020223327A1 (en) 2019-04-30 2020-04-29 Antigen specific cd19-targeted car-t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024205060A Division JP2025028959A (ja) 2019-04-30 2024-11-26 抗原特異的ｃｄ１９標的化ｃａｒ－ｔ細胞

Publications (3)

Publication Number Publication Date
JP2022530773A JP2022530773A (ja) 2022-07-01
JP2022530773A5 true JP2022530773A5 (https=) 2023-05-09
JP7595583B2 JP7595583B2 (ja) 2024-12-06

Family

ID=73029201

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021563640A Active JP7595583B2 (ja) 2019-04-30 2020-04-29 抗原特異的ｃｄ１９標的化ｃａｒ－ｔ細胞
JP2024205060A Pending JP2025028959A (ja) 2019-04-30 2024-11-26 抗原特異的ｃｄ１９標的化ｃａｒ－ｔ細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024205060A Pending JP2025028959A (ja) 2019-04-30 2024-11-26 抗原特異的ｃｄ１９標的化ｃａｒ－ｔ細胞

Country Status (10)

Country Link
EP (1) EP3962955A4 (https=)
JP (2) JP7595583B2 (https=)
KR (1) KR20220005541A (https=)
CN (1) CN114026128A (https=)
AU (1) AU2020265652A1 (https=)
BR (1) BR112021021608A2 (https=)
CA (1) CA3138276A1 (https=)
IL (1) IL287440A (https=)
MX (1) MX2021013368A (https=)
WO (1) WO2020223327A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
CN109735558B (zh) * 2018-12-12 2022-04-15 中南大学 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
WO2022165461A1 (en) * 2021-01-27 2022-08-04 H. Lee Moffitt Cancer Center And Research Institute Inc. Bi-specific car t cells for b cell malignancies
WO2023069936A1 (en) * 2021-10-18 2023-04-27 Kite Pharma, Inc. Signaling domains for chimeric antigen receptors
CN119072319A (zh) * 2021-12-23 2024-12-03 萨那生物技术股份有限公司 用于治疗自身免疫性疾病的嵌合抗原受体(car)t细胞及相关方法
CN115725001A (zh) * 2022-12-08 2023-03-03 湖南光琇高新生命科技有限公司 靶向cd19的嵌合抗原受体、核酸、重组载体及car-t细胞
CN116218786B (zh) * 2023-03-09 2024-01-23 山东大学齐鲁医院 一种多重基因编辑的通用型巨噬细胞及在制备抗肿瘤药物中的应用
WO2025087382A1 (zh) * 2023-10-26 2025-05-01 上海先博生物科技有限公司 靶向cd19的嵌合抗原受体的治疗用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6961490B2 (ja) * 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
AU2016306209B2 (en) * 2015-08-07 2023-07-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific CAR T-cells for solid tumor targeting
CN106467906B (zh) * 2015-08-20 2019-09-27 北京马力喏生物科技有限公司 构建体、转基因淋巴细胞及其制备方法和用途
BR112019006781A2 (pt) 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
EP3568474A1 (en) * 2017-01-10 2019-11-20 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
KR20200027508A (ko) 2017-07-07 2020-03-12 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 돌연변이된 cd28 공동자극 도메인을 갖는 키메라 항원 수용체
JP2021500859A (ja) 2017-09-22 2021-01-14 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Ｎｆｋｂシグナル伝達の増強を伴うキメラ抗原受容体
CN108383914A (zh) * 2018-02-23 2018-08-10 北京美康基免生物科技有限公司 一种基于cd19的嵌合抗原受体及其应用
KR102817092B1 (ko) 2018-03-29 2025-06-09 페이트 세러퓨틱스, 인코포레이티드 조작된 면역 효과기 세포 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2022530773A5 (https=)
KR102879284B1 (ko) 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도
JP2021000103A5 (https=)
JP2020513839A5 (https=)
RU2017105160A (ru) Лечение рака с помощью химерного антигенного рецептора к cd33
IL277398B1 (en) Pd-l1 binding affimers, and uses related thereto
JP2017524367A5 (https=)
JP2022109975A5 (https=)
JP2018527014A5 (https=)
RU2017108903A (ru) Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
US20220389075A1 (en) Engineered t cell receptors and uses thereof
JP2017522879A5 (https=)
JP2019531328A (ja) セレブロン系のヘテロ二量体化可能なキメラ抗原受容体
CA3080109A1 (en) Cd38-directed chimeric antigen receptor constructs
JP2021530233A5 (https=)
JP2024517027A5 (https=)
JP2022538425A5 (https=)
JP2023538116A (ja) Ｅｇｆｒ陽性がんを治療するための組成物及び方法
JP2024534847A5 (https=)
JP2025511409A5 (https=)
JP2025513427A5 (https=)
US20230257441A1 (en) Compositions and methods for treating cancers
WO2021252635A1 (en) Compositions and methods for treating cancers
US20240261330A1 (en) CD19-Directed Chimeric Antigen Receptor Constructs
WO2023147019A2 (en) Compositions and methods for treating mesothelin positive cancers